{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:53:47Z","timestamp":1790376827622,"version":"4.1.0"},"reference-count":76,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glucagon-like peptide 1 receptor agonists (GLP1RAs) have rapidly changed the landscape of diabetes and obesity treatment. Enthusiasm for their use is tempered with concerns regarding their risk for inducing C-cell tumors based on preclinical studies in rodents. A black-box warning from the US Food and Drug Administration recommends against using GLP1RA in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2A or 2B (MEN2), providing clear guidance regarding this cohort of patients. However, emerging data also suggest an increased incidence of differentiated thyroid cancer (DTC) in patients treated with these agents. Other studies, though, have not confirmed an association between GLP1RAs and DTC. With conflicting results concerning thyroid cancer risk, there is no clear consensus regarding the optimal approach to screening patients prior to initiating the medications and\/or evaluating for thyroid cancer during GLP1RA treatment. Within the context of patient cases, this review will summarize the existing data, describe ongoing controversies, and outline future areas for research regarding thyroid cancer risk with GLP1RA use.<\/jats:p>","DOI":"10.1210\/clinem\/dgae722","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T15:20:29Z","timestamp":1728660029000},"page":"e2080-e2087","source":"Crossref","is-referenced-by-count":30,"title":["Approach to the Patient With Thyroid Nodules: Considering GLP-1 Receptor Agonists"],"prefix":"10.1210","volume":"110","author":[{"given":"Clare A","family":"Kelly","sequence":"first","affiliation":[{"name":"Division of Endocrinology, University Hospitals Cleveland Medical Center , Cleveland, OH 44106 \u00a0","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6745-7353","authenticated-orcid":false,"given":"Jennifer A","family":"Sipos","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, The Ohio State University Wexner Medical Center , Columbus, OH 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"issue":"10","key":"2025052713015788200_dgae722-B1","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1210\/jcem-24-10-1076","article-title":"Plasma insulin response to oral and intravenous glucose administration","volume":"24","author":"Elrick","year":"1964","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025052713015788200_dgae722-B2","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2967\/jnumed.106.038679","article-title":"GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting","volume":"48","author":"Korner","year":"2007","journal-title":"J Nucl Med"},{"issue":"1","key":"2025052713015788200_dgae722-B3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1210\/endo.130.1.1309325","article-title":"Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells","volume":"130","author":"Fehmann","year":"1992","journal-title":"Endocrinology"},{"issue":"1","key":"2025052713015788200_dgae722-B4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.metabol.2013.09.010","article-title":"Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells","volume":"63","author":"Lee","year":"2014","journal-title":"Metabolism"},{"issue":"8","key":"2025052713015788200_dgae722-B5","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","article-title":"Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients","volume":"36","author":"Nauck","year":"1993","journal-title":"Diabetologia"},{"issue":"5","key":"2025052713015788200_dgae722-B6","first-page":"E981","article-title":"Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans","volume":"273","author":"Nauck","year":"1997","journal-title":"Am J Physiol"},{"issue":"4","key":"2025052713015788200_dgae722-B7","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/BF01316798","article-title":"Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man","volume":"38","author":"Wettergren","year":"1993","journal-title":"Dig Dis Sci"},{"issue":"3","key":"2025052713015788200_dgae722-B8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","article-title":"Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum","volume":"214","author":"Mentlein","year":"1993","journal-title":"Eur J Biochem"},{"issue":"8","key":"2025052713015788200_dgae722-B9","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/endo.136.8.7628397","article-title":"Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV","volume":"136","author":"Kieffer","year":"1995","journal-title":"Endocrinology"},{"issue":"2","key":"2025052713015788200_dgae722-B10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025052713015788200_dgae722-B11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2337\/diabetes.50.3.609","article-title":"Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients","volume":"50","author":"Vilsboll","year":"2001","journal-title":"Diabetes"},{"issue":"Supplement_1","key":"2025052713015788200_dgae722-B12","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc24-S009","article-title":"9. pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice C","year":"2024","journal-title":"Diabetes Care"},{"issue":"10","key":"2025052713015788200_dgae722-B13","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1185\/03007990802418851","article-title":"Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study","volume":"24","author":"DeFronzo","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"9724","key":"2025052713015788200_dgae722-B14","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","article-title":"Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial","volume":"375","author":"Pratley","year":"2010","journal-title":"Lancet"},{"issue":"9739","key":"2025052713015788200_dgae722-B15","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","article-title":"Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial","volume":"376","author":"Bergenstal","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"2025052713015788200_dgae722-B16","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/ajh.2009.245","article-title":"Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes","volume":"23","author":"Okerson","year":"2010","journal-title":"Am J Hypertens"},{"issue":"6","key":"2025052713015788200_dgae722-B17","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2337\/dc18-2028","article-title":"Changes in Serum calcitonin concentrations, incidence of medullary thyroid carcinoma, and impact of routine calcitonin concentration monitoring in the EXenatide study of cardiovascular event lowering (EXSCEL)","volume":"42","author":"Bethel","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"2025052713015788200_dgae722-B18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1124\/pr.55.1.6","article-title":"International union of pharmacology. XXXV. The glucagon receptor family","volume":"55","author":"Mayo","year":"2003","journal-title":"Pharmacol Rev"},{"issue":"1","key":"2025052713015788200_dgae722-B19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2337\/diabetes.52.1.124","article-title":"Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor","volume":"52","author":"Buteau","year":"2003","journal-title":"Diabetes"},{"issue":"9","key":"2025052713015788200_dgae722-B20","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1210\/endo.137.9.8756532","article-title":"Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line","volume":"137","author":"Crespel","year":"1996","journal-title":"Endocrinology"},{"issue":"4","key":"2025052713015788200_dgae722-B21","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"issue":"3","key":"2025052713015788200_dgae722-B22","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1210\/en.2011-1864","article-title":"GLP-1 receptor agonists and the thyroid: c-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation","volume":"153","author":"Madsen","year":"2012","journal-title":"Endocrinology"},{"issue":"3","key":"2025052713015788200_dgae722-B23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/JME-12-0186","article-title":"Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man","volume":"50","author":"Boess","year":"2013","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"2025052713015788200_dgae722-B24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jc.2011-2407","article-title":"Glucagon like peptide-1 receptor expression in the human thyroid gland","volume":"97","author":"Gier","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025052713015788200_dgae722-B25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/modpathol.2014.113","article-title":"Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas","volume":"28","author":"Waser","year":"2015","journal-title":"Mod Pathol"},{"key":"2025052713015788200_dgae722-B26","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.2147\/OTT.S150701","article-title":"Effects of insulin analogs and glucagon-like peptide-1 receptor agonists on proliferation and cellular energy metabolism in papillary thyroid cancer","volume":"10","author":"He","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"4","key":"2025052713015788200_dgae722-B27","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3803\/EnM.2014.29.4.536","article-title":"Expression of glucagon-like Peptide-1 receptor in papillary thyroid carcinoma and its clinicopathologic significance","volume":"29","author":"Jung","year":"2014","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"8","key":"2025052713015788200_dgae722-B28","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/dc17-1825","article-title":"Neoplasms reported with liraglutide or placebo in people with type 2 diabetes: results from the LEADER randomized trial","volume":"41","author":"Nauck","year":"2018","journal-title":"Diabetes Care"},{"key":"2025052713015788200_dgae722-B29","doi-asserted-by":"crossref","first-page":"927859","DOI":"10.3389\/fendo.2022.927859","article-title":"Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials","volume":"13","author":"Hu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2025052713015788200_dgae722-B30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12020-019-02055-z","article-title":"GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials","volume":"66","author":"Cao","year":"2019","journal-title":"Endocrine"},{"issue":"2","key":"2025052713015788200_dgae722-B31","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2012.09.008","article-title":"A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer","volume":"98","author":"Alves","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"2025052713015788200_dgae722-B32","doi-asserted-by":"crossref","first-page":"102834","DOI":"10.1016\/j.dsx.2023.102834","article-title":"Semaglutide and cancer: a systematic review and meta-analysis","volume":"17","author":"Nagendra","year":"2023","journal-title":"Diabetes Metab Syndr"},{"issue":"3","key":"2025052713015788200_dgae722-B33","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/dom.15382","article-title":"Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Silverii","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2025052713015788200_dgae722-B34","doi-asserted-by":"crossref","first-page":"620","DOI":"10.2337\/dc17-1956","article-title":"No evidence of increase in calcitonin concentrations or development of C-cell malignancy in response to liraglutide for up to 5 years in the LEADER trial","volume":"41","author":"Hegedus","year":"2018","journal-title":"Diabetes Care"},{"issue":"11","key":"2025052713015788200_dgae722-B35","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s40261-022-01202-1","article-title":"Safety of glucagon-like peptide-1 receptor agonists: a real-world study based on the US FDA adverse event reporting system database","volume":"42","author":"Wu","year":"2022","journal-title":"Clin Drug Investig"},{"issue":"1","key":"2025052713015788200_dgae722-B36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"issue":"2","key":"2025052713015788200_dgae722-B37","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 Receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"issue":"1","key":"2025052713015788200_dgae722-B38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jcpt.13259","article-title":"Glucagon-like peptide-1 analogues and thyroid cancer: an analysis of cases reported in the European pharmacovigilance database","volume":"46","author":"Mali","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"2025052713015788200_dgae722-B39","doi-asserted-by":"crossref","first-page":"e55976","DOI":"10.2196\/55976","article-title":"Thyroid hyperplasia and neoplasm adverse events associated with glucagon-like peptide-1 receptor agonists in the food and drug administration adverse event reporting system: retrospective analysis","volume":"5","author":"Makunts","year":"2024","journal-title":"JMIRx Med"},{"issue":"10","key":"2025052713015788200_dgae722-B40","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1210\/clinem\/dgac468","article-title":"Prevalence of subclinical papillary thyroid cancer by age: meta-analysis of autopsy studies","volume":"107","author":"Arroyo","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025052713015788200_dgae722-B41","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/jnci\/djz202","article-title":"Impact of overweight and obesity on US papillary thyroid cancer incidence trends (1995-2015)","volume":"112","author":"Kitahara","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2025052713015788200_dgae722-B42","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/2042098612446473","article-title":"Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance","volume":"3","author":"Dore","year":"2012","journal-title":"Ther Adv Drug Saf"},{"issue":"1","key":"2025052713015788200_dgae722-B43","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/dom.15292","article-title":"Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: a population-based cohort study","volume":"26","author":"Bea","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2025052713015788200_dgae722-B44","doi-asserted-by":"crossref","first-page":"e078225","DOI":"10.1136\/bmj-2023-078225","article-title":"Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: scandinavian cohort study","volume":"385","author":"Pasternak","year":"2024","journal-title":"BMJ"},{"issue":"4","key":"2025052713015788200_dgae722-B45","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/dom.13597","article-title":"Exenatide use and incidence of pancreatic and thyroid cancer: a retrospective cohort study","volume":"21","author":"Liang","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2025052713015788200_dgae722-B46","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.2147\/DMSO.S305496","article-title":"Risk of thyroid cancer associated with use of liraglutide and other antidiabetic drugs in a US commercially insured population","volume":"14","author":"Funch","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"5","key":"2025052713015788200_dgae722-B47","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.2337\/dc22-2454","article-title":"Comment on bezin et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes care 2023;46:384-390","volume":"46","author":"Endo","year":"2023","journal-title":"Diabetes Care"},{"issue":"4","key":"2025052713015788200_dgae722-B48","first-page":"403","article-title":"Glucagon-Like peptide-1 receptor agonists and thyroid cancer: a narrative review","volume":"34","author":"Espinosa De Ycaza","year":"2024","journal-title":"Thyroid"},{"issue":"5","key":"2025052713015788200_dgae722-B49","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.2337\/dc22-2300","article-title":"Comment on bezin et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes care 2023;46:384-390","volume":"46","author":"Goldenberg","year":"2023","journal-title":"Diabetes Care"},{"issue":"2","key":"2025052713015788200_dgae722-B50","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2337\/dci22-0052","article-title":"Putting GLP-1 RAs and thyroid cancer in context: additional evidence and remaining doubts","volume":"46","author":"Thompson","year":"2023","journal-title":"Diabetes Care"},{"issue":"5","key":"2025052713015788200_dgae722-B51","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.2337\/dc23-0134","article-title":"Comment on bezin et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes care 2023;46:384-390","volume":"46","author":"Smits","year":"2023","journal-title":"Diabetes Care"},{"issue":"10","key":"2025052713015788200_dgae722-B52","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1089\/thy.2019.0591","article-title":"Medullary thyroid carcinoma surveillance study: a case-series registry","volume":"30","author":"Hale","year":"2020","journal-title":"Thyroid"},{"issue":"14","key":"2025052713015788200_dgae722-B53","doi-asserted-by":"crossref","first-page":"221","DOI":"10.14715\/cmb\/2023.69.14.37","article-title":"GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells","volume":"69","author":"Zhang","year":"2023","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"1","key":"2025052713015788200_dgae722-B54","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1186\/s12885-023-11077-w","article-title":"High glucose promotes the progression of colorectal cancer by activating the BMP4 signaling and inhibited by glucagon-like peptide-1 receptor agonist","volume":"23","author":"Ma","year":"2023","journal-title":"BMC Cancer"},{"issue":"9","key":"2025052713015788200_dgae722-B55","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1210\/en.2011-1201","article-title":"Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells","volume":"152","author":"Koehler","year":"2011","journal-title":"Endocrinology"},{"issue":"2","key":"2025052713015788200_dgae722-B56","first-page":"91","article-title":"Glucagon-like peptide-1 analogues inhibit proliferation and increase apoptosis of human prostate cancer cells in vitro","volume":"125","author":"Li","year":"2017","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2025052713015788200_dgae722-B57","doi-asserted-by":"crossref","first-page":"173102","DOI":"10.1016\/j.ejphar.2020.173102","article-title":"Synergistic anti-tumor effects of liraglutide, a glucagon-like peptide-1 receptor agonist, along with docetaxel on LNCaP prostate cancer cell line","volume":"878","author":"Eftekhari","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"2025052713015788200_dgae722-B58","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1530\/EC-17-0294","article-title":"Exenatide modulates tumor-endothelial cell interactions in human ovarian cancer cells","volume":"6","author":"Kosowska","year":"2017","journal-title":"Endocr Connect"},{"issue":"10","key":"2025052713015788200_dgae722-B59","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31083\/j.fbl2810259","article-title":"The effect of liraglutide on lung cancer and its potential protective effect on high glucose-induced lung senescence and oxidative damage","volume":"28","author":"Pu","year":"2023","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"9","key":"2025052713015788200_dgae722-B60","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/dom.12291","article-title":"Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3 K\/akt pathway","volume":"16","author":"Zhao","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2025052713015788200_dgae722-B61","doi-asserted-by":"crossref","first-page":"E1431","DOI":"10.1152\/ajpendo.00017.2014","article-title":"Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner","volume":"306","author":"Zhao","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2025052713015788200_dgae722-B62","doi-asserted-by":"crossref","first-page":"103242","DOI":"10.1016\/j.ebiom.2021.103242","article-title":"Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by exendin-4: a translational case-control study","volume":"65","author":"Mao","year":"2021","journal-title":"EBioMedicine"},{"key":"2025052713015788200_dgae722-B63","doi-asserted-by":"crossref","first-page":"793530","DOI":"10.3389\/fonc.2021.793530","article-title":"The GLP-1R agonist exendin-4 attenuates hyperglycemia-induced chemoresistance in human endometrial cancer cells through ROS-mediated mitochondrial pathway","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"issue":"8","key":"2025052713015788200_dgae722-B64","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1056\/NEJM199302253280807","article-title":"Management of a solitary thyroid nodule","volume":"328","author":"Mazzaferri","year":"1993","journal-title":"N Engl J Med"},{"issue":"18","key":"2025052713015788200_dgae722-B65","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2017.0562","article-title":"Screening for thyroid cancer: updated evidence report and systematic review for the US preventive services task force","volume":"317","author":"Lin","year":"2017","journal-title":"JAMA"},{"issue":"18","key":"2025052713015788200_dgae722-B66","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.2017.4011","article-title":"Screening for thyroid cancer: uS preventive services task force recommendation statement","volume":"317","author":"Force","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"2025052713015788200_dgae722-B67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2015.09.010","article-title":"Basal and stimulated calcitonin levels in patients with type 2 diabetes did not change during 1 year of Liraglutide treatment","volume":"65","author":"Lunati","year":"2016","journal-title":"Metabolism"},{"issue":"1","key":"2025052713015788200_dgae722-B68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.2910340102","article-title":"UICC workshop on the evaluation of screening programmes for cancer","volume":"34","author":"Prorok","year":"1984","journal-title":"Int J Cancer"},{"issue":"1","key":"2025052713015788200_dgae722-B69","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S2213-8587(19)30324-9","article-title":"Screening for differentiated thyroid cancer in selected populations","volume":"8","author":"Lamartina","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2025052713015788200_dgae722-B70","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1634\/theoncologist.2010-0344","article-title":"Early diagnosis of medullary thyroid carcinoma: is systematic calcitonin screening appropriate in patients with nodular thyroid disease?","volume":"16","author":"Costante","year":"2011","journal-title":"Oncologist"},{"issue":"3","key":"2025052713015788200_dgae722-B71","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1373\/clinchem.2010.151688","article-title":"Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer","volume":"57","author":"Kratzsch","year":"2011","journal-title":"Clin Chem"},{"issue":"8","key":"2025052713015788200_dgae722-B72","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1210\/jc.2014-1278","article-title":"Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer","volume":"99","author":"Machens","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025052713015788200_dgae722-B73","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1373\/clinchem.2016.270009","article-title":"United States and European multicenter prospective study for the analytical performance and clinical validation of a novel sensitive fully automated immunoassay for calcitonin","volume":"63","author":"Kahaly","year":"2017","journal-title":"Clin Chem"},{"issue":"2","key":"2025052713015788200_dgae722-B74","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/jc.2003-030709","article-title":"Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects","volume":"89","author":"Karanikas","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025052713015788200_dgae722-B75","first-page":"301","article-title":"Increased plasma calcitonin in early acute renal failure","volume":"49","author":"Ardaillou","year":"1975","journal-title":"Clin Sci Mol Med"},{"issue":"6","key":"2025052713015788200_dgae722-B76","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1530\/EJE-07-0566","article-title":"Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking","volume":"157","author":"d'Herbomez","year":"2007","journal-title":"Eur J Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae722\/60038957\/dgae722.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/6\/e2080\/60038957\/dgae722.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/6\/e2080\/60038957\/dgae722.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T13:04:06Z","timestamp":1748351046000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/6\/e2080\/7821115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":76,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,10,14]]},"published-print":{"date-parts":[[2025,5,19]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae722","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2024,10,14]]}}}